BRAF and non-small cell lung carcinoma: The BRAF p.V600E hotspot mutation is reported in 3% of NSCLC and alters residues important in AKT-mediated BRAF phosphorylation, suggesting that the disruption of AKT-induced BRAF inhibition plays a role in malignant transformation [28], [30].